From Retina Consultants of Houston, Houston, TX (SIRL, DMB, CCW); Northern California Retina Vitreous Associates, Mountain View, CA (RNK); Clearside Biomedical, Alpharetta, GA (GN); and Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX (DMB, CCW).
This study was supported by a research grant from Clearside Biomedical (Alpharetta, GA). The funding organization had no role in the conduct of this research.
Dr. Khurana has received grants and personal fees from Allergan, Regeneron, and Santen, as well as personal fees from Genetech, outside the submitted work. Dr. Noronha is an employee of Clearside Biomedical and has a patent related to the drug, CLS-TA, and to the method of suprachoroidal administration to treat inflammatory conditions pending. Dr. Brown has received grants and personal fees from ADverum, Alcon, Akkegro, Allergan, Apellis, Boehringer Ingelheim, Genentech, Heidelberg Engineering, Novartis, OHR, Ophthotech, Regeneron, Regenxbio, Roche, Santen, SciFluor, Taiwan Liposome, Tyrogenex, and Clearside Biomedical; grants from Aerpio, Alderya, Astellas, Aura, Bayer, Chiltern, GlaxoSmithKline, Iconic Therapeutics, INC Research, Johns Hopkins, NEI, Ora, Jaeb Center for Health Research, and pSivida; and personal fees from Chengdu Kanghong Biotechnology, Coda Therapeutics, Johnson and Johnson, Merck, Notal Vision, Optos, Optovue, Pfizer, Samsung Bioepis, Senju Pharmaceuticals, Stealth BioTherapeutics, Thrombogenics, and Zeiss outside the submitted work. Dr. Wykoff has received grants from Adverum Biotechnologies, Aerpio Therapeutics, Aldeyra Therapeutics, Alimera Sciences, Allegro Ophthalmics, Apellis Pharmaceutical, Astellas Pharma, Aura Biosciences, Boehrigner Ingelheim, Chiltern International, GlaxoSmithKline, Heidelberg Engineering, Iconic Therapeutics, INC Research, Johns Hopkins, NEI, Novartis International AG, Ophthotech Corportation, OHR Pharmaceutical, Regenexbio, Ora, pSivida, SciFluor Life Sciences, Taiwan Liposome Company, and Tyrogenex; grants and personal fees from Alcon Laboratories, Allergan, Genentech, Regeneron, Roche, Santen, and Clearside Biomedical; and personal fees from Alnylam Pharmaceuticals, Atheneum Partners, Bayer AG, Consultants, CORCEPT, Destum Partners, D.O.R.C., Hexal AG, k2c Medical Communications, Notal Vision, Novo Nordisk, ONL Therapeutics, Prime Education, personal fees from System Analytic, ThromboGenics NV, and Valeant Pharmaceuticals outside the submitted work. Dr. Lampen reports no relevant financial disclosures.
Address correspondence to Charles C. Wykoff, MD, PhD, 6560 Fannin Street, Suite 750, Houston, TX 77030; email: